- Car Insurance Scofflaws Raise Health Reform Doubt
- Rush Starts as Holiday Shopping Season Revs Up
- US Markets Bracing for Selloff on Dubai Debt Worries
- US Dollar Falls to 14-Year Low Against the Yen
- ING Prices Share Issue at Hefty Discount
- UK's Darling to Downgrade 2009 Growth Forecast
- Tommy Hilfiger's Estate in Conn. Sells for $20 Million
- Cheap Robotic Hamsters Are Holiday's Unlikely Craze
- Fannie Mae to Tighten Lending Standards: Report
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
MOST SHARED
- No Thanksgiving Rest for Retailers in Sales Race
- Banks Play Down Dubai Exposure, Investors Still Wary
- UK's Darling to Downgrade 2009 Growth Forecast
- US Markets Bracing for Selloff On Worries About Dubai's Debt
- More Asia Executives Resigned to Economy Flights: Survey
- Attraction of Switzerland to Businesses
- Acer Launches Android Phone, Says Targets on Track
- ING Prices Share Issue at Hefty Discount
Text Size 
The Food and Drug Administration has approved a highly anticipated blood thinner from Eli Lilly after more than 18 months of review.
 |
The approval makes Lilly's [LLY
Loading...
()
] Effient the first real competition to the blood thinner Plavix, the world's second-best selling medication made by Sanofi-Aventis [SNY
Loading...
()
] and Bristol-Myers Squibb [BMY
Loading...
()
] .
The FDA delayed its decision on Effient multiple times as reviewers weighed the drug's benefits versus its risks
A study of over 13,000 patients conducted by Lilly found that Effient prevents more heart attacks than Plavix, but also causes more internal bleeding.
The FDA says Effient will carry a boxed warning to alert physicians to the risks of potentially fatal bleeding.
Print
Email
- What you need to know.
- Social enterprises are becoming a new asset class for the ethically-minded.
- Ever wished your cab driver would stop nattering and just get to where you're going? Well that moment is near(er).
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- More shoppers than ever plan to comparison-shop this season. Who will benefit?
- It may be the most unusual guide to business you'll read.
Data is a real-time snapshot *Data is delayed at least 15 minutes